Is the biotech market boom back? These three companies bucked the trend to "break through" the NASDAQ

Read: New Crown Pneumonia Can't Stop the Progress of Drug Research and Development!the global epidemic of the new crown outbreak, or to some extent affecting the clinical progress of some drug development, but the pace of the listing of biotech companies has not been suspendedfirst of all, the Hong Kong stock market showed great resilienceSince the outbreak, Nocheng Jianhua, Kangfang Bio, Peijia Medical, Pioneering Pharmaceuticals 4 biotech companies have logged on to the Hong Kong Stock Exchange, can be said to be highly sought after by the marketThe co-creation board is also lively, Junshi creature, Shenzhou cell, Kangsino, the river creature ..The constant news of biotech IPO is eye-catchingis the U.Sstock market worth mentioning right nowRecently, while COVID-19 caused widespread chaos on Wall Street, biotech companies bucked the trend and "pushed" the NASDAQfirst legendary creature, the Chinese CAR-T therapy company will officially launch on June 4thAnd according to the latest news, after the legendary creatures, two other biotech companies are also on the NASDAQ after the hot iron announcement: Repare, which specializes in synthetic lethality, and Forma, a first-stage rare disease companycombined, the three companies raised $600 millionBehind this, the three companies that went back against the listing, what is the end of the story?1, Legendary Bio
Legendary Bio' listing by Morgan Stanley, JPMorgan Chase, Jeffery as co-lead underwriters, the stock code is "LEGN."'s latest ipo filing on May 29th, it expects to issue 18.425 million ADS (American Depositary shares, each OF which represent 8 class A common shares), with a price of between $18-20/ADS and a capital raising of $332-369 million, for a market capitalization of about $2.6 billionit is understood that Legendary Bio's parent company, Kingsley (1548HK) will purchase $12 million of common stock at the initial public offering price per share, and upon completion of the IPO, Kingsley will hold 66% of Legendary Bio's common stock (i.e66% voting rights), meaning legendary creatures will become a "controlled company" as defined by the NASDAQ trading rulesFounded in 2014,Legendary Bio is one of the own brands of CRO Company Kingsley, dedicated to the discovery and development of new cell therapies for blood tumors, infectious diseases and autoimmune diseasesAccording to the latest data from the prospectus, there are many pipelines in the field of cell therapy in China and the United States, and the fastest progress is BCMA-CAR-T therapy LCAR-B38MLegendary Bio(Source:: Company's Official Website), news of Legendary Bio's listing in the U.Sspread as early as March, when the company completed a $150 million pre-IPO round of financing, valuing it at $1.95 billionAt present, after the fist products obtained a more definite breakthrough, legendary biological choice to go to the United States listing for LCAR-B38M approved after the production, commercial promotion, multi-party cooperation and so on to provide financial supportof course, in the face of LCAR-B38M's pending application, and the expected profits from the new drug's launch, it's also time for Kingsley, the parent company with the largest share of Legendary Bio, to spin off and go public in the USRepare Therapeutics,2, RepareTherapeuticsGenenare Therapeutics, filed a listing application with the U.S SEC on Friday (May 29) to raise up to $100 million through an initial public offering RepareTherapeutics, who is co-bookkeeper of Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler, has been issued under the tickle code RPTX and has not yet determined the price range for the issue was founded in 2016 as a precision oncology company dedicated to developing new synthetic lethal targeting therapies It uses a genome-wide, CRISPR-enabled SNIPRx ® platform to systematically identify and develop highly targeted cancer therapies for genomic instability, including DNA damage repair synthetic lethaltreatment is that while tumors can tolerate a single defect at the DNA level, multiple combinations of defects can effectively lead to the death of malignant tumor cells The Lynparza drug, developed by AstraZeneca and Mercado, is the result of killing tumors by "syntheticly" suppressing PARP proteins in cancer cells that have mutated RepareTherapeutics specializes in finding genes that can "synthesize lethality." In terms of research and development pipelines, the company's heavy-weight research product, the RP-3500, uses this strategy, which is expected to be a potential leading ATR inhibitor Repare (Source: , RepareTherapeutics has previously received a cumulative total of more than $140 million in financing, once on the industry's best-known annual "Fierce Biotech" list of "Biotech" (2017 Fierce15) In September last year, RepareTherapeutics announced the completion of the $82.5 million Round B financing, which it said would be used to push the ATR inhibitor RP-3500 into clinical phase by 2020 also note that just days before RepareTherapeutics filed its listing application, it announced that it had reached a global lying partnership with BMS to develop innovative "synthetic lethal" precision therapy The two companies will use Repare's proprietary CRISPR-supported whole genome-supported synthetic lethal target discovery platform, SNIPRx®, to jointly identify multiple synthetic lethal precision tumor drug targets for candidate drugs agreement, BMS will pay an advance of $65 million, including a $15 million equity investment in Repare, while Repare will be eligible for licensing fees of up to approximately $3 billion, discovery, development, regulatory and sales-based milestones, and a royalty for the net sale of each product commercialized by BMS 3, Forma Therapeutics another ipo announcement is FormaTherapeutics , a company that has been working on rare blood diseases and cancer treatments for more than a decade, completed a $100 million D-round funding late last year Six months later, it has set its sights on Nasdaq, raising $150 million under the ticker code "FMTX" The core of Forma lies in the development of sickle cell disease (SCD) drugs In general, the field of blood disease receives little attention, and the patient is characterized by anatypical hemoglobin molecule, which can distort red blood cells into a sickle or crescent But last year, the FDA approved two new drugs to treat the disease, Novartis' Adakveo and GlobalBlood's Oxbryta Forma in the of the pipeline (source: corporate website) from the research pipeline, Forma is mainly in the research of one of the drugs in the research is FT-4202, the drug is currently in Phase 1 testing The drug differs from the two approved drugs in that it is designed to activate an enzyme called PKR, improve the metabolism and function of red blood cells, and improve their survival, which is expected to increase hemoglobin levels and reduce the risk of blood vessel blockages In other words, the drug's goal is to change the course of sickle cell disease, rather than addressing symptoms such as infection, inflammation and anemia At the same time , Forma is also exploring the application of FT-4202 in beta thalassemia In addition to FT-4202, Forma's research products also cover disease sepsis, NASH and other diseases, such as THE BET inhibitor CC-95775 developed in collaboration with BMS for the treatment of non-Hodgkin's lymphoma, and the KRAS inhibitor BI-1701963 developed in collaboration with Bollinger Ingehan